Heart failure with preserved and slightly impaired ejection fraction and cardiovascular events: Pathogenetic interrelations as a part of the cardiovascular continuum

Aim. To evaluate the effect of decompensated HF with preserved or slightly impaired EF on the risk of cardiovascular complications during a 5-year follow-up. Materials and methods. 33 patients with arterial hypertension and HF with preserved or slightly impaired EF (NT-proBNP ≥125 pg/ml, mean, 500.1±590.32 pg/ml and EF ≥40%, mean, 57.0±10.29%) were observed for 5 years. EchoCG, markers of immune inflammation and hormonal changes (endothelin, tumor necrosis factor (TNF), interleukin-6 (IL-6), aldosterone, renin) were evaluated at baseline. The endpoint was development of acute fatal and non-fatal cardiovascular events (CVEs). Ue one-way regression analysis was used to identify predictors of the risk for CVEs. The ROC analysis was used to determine “threshold levels” of significant predictors for this risk. Results. During the 5-year follow-up period, CVEs developed in 13 (39.4%) patients. Ue CVE predictors included baseline increases in creatinine and IL-6, NT-proBNP and a greater decrease in EF (р<0.05 for each factor). The ROC analysis showed that NT-proBNP ≥235.8 pg/ml was the most effective predictor of CVEs (sensitivity, 92.3%; specificity, 60%; area under the curve, 0.736; р=0.045). Comparison of patient subgroups with baseline values of NT-proBNP higher or lower than the predetermined threshold (n=13 and n=20, respectively) detected an association of more severe HF decompensa tion with activation of neurohormonal systems and a worse prognosis. Specifically, patients with higher NT-proBNP had also higher levels of IL-6 (р=0.048) and creatinine (р=0.047) and a greater proportion of patients with CVEs (р=0.008). Conclusions. Possible mechanisms of cardiovascular complications in HF with preserved or slightly impaired ej ection fraction include activation of immune inflammatory systems. In its turn, the process of heart failure decompensation itself can become a factor intensifying production of proinflammatory cytokines. Heart wall tension may play a special role in the increased activity of inflammatory process and exert an independent effect on development of acute complications in CVDs.

СНсФВ, СНпФВ, сердечно-сосудистые события, патогенетические взаимосвязи, системное воспаление, HFpEF, HFiEF, cardiovascular events, pathogenetic interrelations, systemic inflammation

1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011;12 (2):63-8. DOI:10.18087/ rhfj.2011.2.1510

2. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18 (1):3-40. DOI:10.18087/rhfj.2017.1.2346

3. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255-66

4. Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13. DOI:10.15829/1560-4071-2016-8-7-13

5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129-200. DOI:10.1093/eurheartj/ehw128.

6. Терещенко С. Н., Жиров И. В., Насонова С. Н., Николаева О. А., Ледяхова М. В. Патофизиология острой сердечной недостаточности. Что нового? Российский Кардиологический Журнал. 2016; (9 (137)): 52-64

7. Lim SL, Lam CSP, Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36 (31):2050-60. DOI:10.1093/eurheartj/ehv132.

8. Gallet R, de Couto G, Simsolo E, Valle J, Sun B, Liu W et al. Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. JACC Basic Transl Sci. 2016;1 (1-2):14-28. DOI:10.1016/ j.jacbts.2016.01.003.

9. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4 (4):312-24. DOI:10.1016/j.jchf.2015.10.007.

10. Franssen C, Gonzalez Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J. 2016;24 (4):259-67. DOI:10.1007/s12471-016-0812-z.

11. Tokitsu T, Yamamoto E, Hirata Y, Kusaka H, Fujisue K, Sueta D et al. Clinical significance of pulse pressure in patients with heart failure with preserved left ventricular ejection fraction. Eur J Heart Fail. 2016;18 (11):1353-61. DOI:10.1002/ejhf.559.

12. Pries AR, Reglin B. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J. 2017;38 (7) :478-88. DOI: 10.1093/eurheartj /ehv760.

13. Garg A, Virmani D, Agrawal S, Agarwal C, Sharma A, Stefanini G et al. Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology. 2017;136 (3): 192-203. DOI: 10.1159/000450573.

14. Ruiz Ortega RA, Manzano L, Montero-Pérez-Barquero M. [Diagnosis of acute heart failure and relevance of biomarkers in elderly patients]. Med Clin (Barc). 2014; 142 Suppl 1:20-5. DOI:10.1016/S0025-7753 (14) 70078-8.

15. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012;17 (2):177-90. DOI:10.1007/s10741-011-9261-3.

16. Ganda A, Onat D, Demmer RT, Wan E, Vittorio TJ, Sabbah HN et al. Venous congestion and endothelial cell activation in acute decompensated heart failure. Curr Heart Fail Rep. 2010;7 (2):66-74. DOI: 10.1007/s11897-010-0009-5.

17. Poredos P, Jezovnik MK. The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease. Curr Vasc Pharmacol. 2016;14 (6):534-46.

18. Poredos P, Spirkoska A, Lezaic L, Mijovski MB, Jezovnik MK. Patients with an Inflamed Atherosclerotic Plaque have Increased Levels of Circulating Inflammatory Markers. J Atheroscler Thromb. 2017;24 (1):39-46. DOI:10.5551/jat.34884.

19. Opstad TB, Arnesen H, Pettersen A.Å, Seljeflot I. Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study. Metab Syndr Relat Disord. 2016;14 (5):242-8. DOI:10.1089/met.2015.0130.

20. Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol. 2016;214:301-6. DOI: 10.1016/j.ijcard.2016.03.186.